Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

China

As a participant in the lifesciences and healthcare industry, you know that discovery and innovation are key to finding lasting health solutions. Yet due to the highly regulated nature of the industry, you - a corporate, investor or start-up - must overcome complex administrative, compliance and liability hurdles before your products and services can come to market.

With more than 300 lawyers, patent attorneys, scientists and academics across CMS and the support of the Lifesciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your business. Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics.

With active memberships in the major industry associations such as the ABPI, ABHI, BIVDA, PAGB, EUCOMED and EFPIA, we help shape the legal frameworks impacting the lifesciences sector. We regularly advise our clients on their day to day operational needs such as support with public sector procurement, patent prosecution and enforcement, commercial agreements, tax and transfer pricing, and regulatory advice. Equally, when you need lifesciences specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less
11/07/2016
Ex­pect­a­tion of a Faster Growth of Health Food in Near Fu­ture
The Ad­min­is­trat­ive Meas­ures for the Re­gis­tra­tion and Re­cordal of Health Food (“Meas­ures”) ad­op­ted and pro­mul­gated by China Food and Drug Ad­min­is­tra­tion ("CF­DA") on 4 Feb­ru­ary 2016 have come in­to force...
05/04/2016
New GCP of Med­ic­al Devices
On 23 March 2016, the China Food and Drugs Ad­min­is­tra­tion (“CF­DA”) and Na­tion­al Health and Fam­ily Plan­ning Com­mis­sion (“NHFPC”) jointly is­sued the new Good Clin­ic­al Prac­tice of Med­ic­al Devices...
05/04/2016
China En­cour­ages In­nov­at­ive Drug by Modi­fy­ing Its Drug Clas­si­fic­a­tion Rules
Fol­low­ing the new rules of clas­si­fic­a­tion of med­ic­al devices ef­fect­ive as of 1st Janu­ary 2016, the China Food and Drug Ad­min­is­tra­tion (“CF­DA”) is­sued a cir­cu­lar re­gard­ing the re­form of chem­ic­al drug...

Feed

Show only
06 May 2021
High­lights on New Reg­u­la­tions on Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al...
On 18 March 2021, the State Coun­cil pro­mul­gated the Reg­u­la­tions on Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices (Re­vised in 2021), which will take ef­fect on 1 June 2021 (the "New Med­ic­al Device Reg­u­la­tions")...
30/04/2021
High­lights on New Reg­u­la­tions on Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al...
On 18 March 2021, the State Coun­cil pro­mul­gated the Reg­u­la­tions on Su­per­vi­sion and Ad­min­is­tra­tion of Med­ic­al Devices (Re­vised in 2021), which will take ef­fect on 1 June 2021 (the "New Med­ic­al Device Reg­u­la­tions")...
21 April 2021
Belt and Road Ini­ti­at­ive
China’s Belt and Road Ini­ti­at­ive (BRI) con­tin­ues to evolve, of­fer­ing new op­por­tun­it­ies for na­tions, com­munit­ies and busi­nessesIt is now ex­pli­citly aligned with many areas that are in­creas­ing pri­or­it­ies for in­ter­na­tion­al busi­nesses, such as ESG prin­ciples and sus­tain­ab­il­ity. But in 2020 it faces un­pre­ced­en­ted head­winds, in­clud­ing the glob­al pan­dem­ic and trade dis­putes.As a lead­er in many Belt and Road sec­tors, CMS has polled and in­ter­viewed over 500 BRI par­ti­cipants around the world, about their cur­rent think­ing on BRI and the pro­spects they see for it. Our find­ings from China, Asia Pa­cific, Cent­ral and East­ern Europe, Middle East, North Africa re­gion and Lat­in Amer­ica are avail­able now.Re­port on Africa will be pub­lished in the com­ing months.me­di­um­me­di­um­me­di­um­me­di­um­me­di­um­me­di­um
20 April 2021
COV­ID-19 vac­cin­a­tion and test­ing in China - em­ploy­ment law per­spect­ive
Vac­cin­a­tion 1. What op­tions does the em­ploy­er have to en­cour­age em­ploy­ees to be vac­cin­ated? Can the em­ploy­er provide a fin­an­cial in­cent­ive to em­ploy­ees?  The em­ploy­er may ex­plain the im­port­ance of...
Comparable
23 March 2021
On the Pulse
Wel­come to ‘On the Pulse’ de­livered by the Glob­al Life Sci­ences & Health­care Sec­tor Group A video/pod­cast series, On the Pulse, brings to­geth­er CMS law­yers and ex­perts to dis­cuss key in­dustry top­ics...
23 March 2021
The En­larged Board of the European Pat­ent Of­fice has giv­en a mo­ment­ous...
The En­larged Board of the European Pat­ent Of­fice heard or­al ar­gu­ments in Ju­ly 2020 con­cern­ing pat­entab­il­ity of a com­puter soft­ware in­ven­tion.  This rare event was video streamed to over 1600 pat­ent stake­hold­ers...
09 March 2021
Chinese Tax Reg­u­la­tion Up­date - Janu­ary & Feb­ru­ary 2021
The latest de­vel­op­ment in China Tax Reg­u­la­tion mainly in­cludes: Cai Guan Shui [2020] No. 54 Caishui [2021] No. 3 Please click here to read the full art­icle.
15 January 2021
CMS, China ranks in ten prac­tice areas in Leg­al 500 Asia Pa­cific
We are pleased to an­nounce that CMS, China has been ranked and re­com­men­ded in ten areas in the Leg­al 500 Asia Pa­cific 2021 edi­tion. We con­tin­ue to be re­cog­nised in the areas of An­ti­trust and com­pet­i­tion...
14 December 2020
Di­git­al health apps and telemedi­cine in China
Di­git­al Health Apps/Soft­ware 1. How is the soft­ware with­in di­git­al health apps clas­si­fied in your jur­is­dic­tion, and what reg­u­la­tion(s) ap­ply? 1.1 Is it con­sidered a “med­ic­al device” or a “product”...
Comparable
09 December 2020
In­nov­at­ive De­vel­op­ment Plan of Im­ple­ment­ing Hong Kong or Ma­cao Mar­keted...
On 25 Novem­ber 2020, eight min­is­ters and au­thor­it­ies at na­tion­al level[1]is­sued the Work Plan for the In­nov­at­ive De­vel­op­ment of the Reg­u­la­tion of Drugs and Med­ic­al Devices in the Guang­dong-Hong Kong-Ma­cao...
9 December 2020
In­nov­at­ive De­vel­op­ment Plan of Im­ple­ment­ing Hong Kong or Ma­cao Mar­keted...
On 25 Novem­ber 2020, eight min­is­ters and au­thor­it­ies at na­tion­al level[1]is­sued the Work Plan for the In­nov­at­ive De­vel­op­ment of the Reg­u­la­tion of Drugs and Med­ic­al Devices in the Guang­dong-Hong Kong-Ma­cao...
04 December 2020
High­lights on Veter­in­ary Phar­ma­co­poeia (2020 Edi­tion)
On 26 Novem­ber 2020, the Min­istry of Ag­ri­cul­ture and Rur­al Af­fairs of the People’s Re­pub­lic of China (“MOA”) pro­mul­gated the Veter­in­ary Phar­ma­co­poeia of the People's Re­pub­lic of China (2020 Edi­tion)...